Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small ...

We’ll also explore the company’s innovative approach to treating cancer, particularly those driven by KRAS mutations, and why Prof. Peled’s addition could be a game-changer. The recent appointment of ...

New research from the University of Ottawa sees mRNA and RNAi-based therapies delivered in single treatment, paving way for treatment of cancer, cardiovascular diseases.

One of their distinctive abilities is detaching a portion of the body to escape from predators. A few species of brittle ...

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded ...

Researchers at the University of Ottawa have figured out how to use mRNA and RNAI-based treatments to treat complex illnesses ...

Researchers have recently revealed new insights into how brittle stars can reversibly adjust the pliability of their tissues.

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the ...

Opens in a new tab or window In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led ...